Compile Data Set for Download or QSAR
Report error Found 30 Enz. Inhib. hit(s) with all data for entry = 5982
TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103469(US8552004, 2.07)
Affinity DataIC50: 2.58nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103481(US8552004, 2.08)
Affinity DataIC50: 2.76nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM60432(BDBM50468001 | US8552004, 2.02 | US11236089, Compo...)
Affinity DataIC50: 3.75nMpH: 7.4 T: 2°CAssay Description:ATR for use in the in vitro enzyme assay was obtained from HeLa nuclear extract (CIL Biotech, Mons, Belgium) by immunoprecipitation with rabbit polyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103467(US8552004, 2.03)
Affinity DataIC50: 5.61nMpH: 7.4 T: 2°CAssay Description:ATR for use in the in vitro enzyme assay was obtained from HeLa nuclear extract (CIL Biotech, Mons, Belgium) by immunoprecipitation with rabbit polyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103467(US8552004, 2.03)
Affinity DataIC50: 7.05nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103483(US8552004, 3.02)
Affinity DataIC50: 8.43nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103490(US8552004, 5.09)
Affinity DataIC50: 10.1nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103472(US8552004, 3.02 | US8552004, 3.01)
Affinity DataIC50: 12.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103480(US8552004, 2.06)
Affinity DataIC50: 12.9nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103471(US8552004, 2.11 | BDBM50456371)
Affinity DataIC50: 13.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103488(US8552004, 5.04)
Affinity DataIC50: 16.2nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103491(US8552004, 5.08)
Affinity DataIC50: 18.0nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103487(US8552004, 5.05)
Affinity DataIC50: 18.3nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103466(US8552004, 2.04)
Affinity DataIC50: 21.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103477(US8552004, 5.07)
Affinity DataIC50: 29.0nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103476(US8552004, 5.03)
Affinity DataIC50: 33.1nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103465(US8552004, 1.01)
Affinity DataIC50: 34.0nMpH: 7.4 T: 2°CAssay Description:ATR for use in the in vitro enzyme assay was obtained from HeLa nuclear extract (CIL Biotech, Mons, Belgium) by immunoprecipitation with rabbit polyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103484(US8552004, 4.02)
Affinity DataIC50: 39.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103486(US8552004, 5.06)
Affinity DataIC50: 44.4nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103489(US8552004, 5.10)
Affinity DataIC50: 47.0nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103474(US8552004, 4.03)
Affinity DataIC50: 51.1nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103473(US8552004, 4.01)
Affinity DataIC50: 53.6nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM60432(BDBM50468001 | US8552004, 2.02 | US11236089, Compo...)
Affinity DataIC50: 58.3nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103475(US8552004, 5.01)
Affinity DataIC50: 62.5nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103485(US8552004, 5.02)
Affinity DataIC50: 70.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103468(US8552004, 2.05)
Affinity DataIC50: 75.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103482(US8552004, 2.10)
Affinity DataIC50: 109nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103470(US8552004, 2.09)
Affinity DataIC50: 159nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM60433(US8552004, 2.01 | BDBM103466)
Affinity DataIC50: 236nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase ATR(Human)
Astrazeneca

US Patent
LigandPNGBDBM103465(US8552004, 1.01)
Affinity DataIC50: 581nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/3/2014
Entry Details
Go to US Patent